Chase et al., “Effect of monophosphoryl lipid A on host resistance to bacterial infection,” Infection and Immunity 53(3):711-712, Sep. 1986. |
Gustafson et al., “Monophosphoryl lipid A as a prophylactic for sepsis and septic shock,” Progress in Clinical and Biological Research, Bacterial Endotoxins: Lipopolysaccharides, 392:567-579, 1995. |
Gustafson and Rhodes, “A rationale for the prophylactic use of monophosphoryl lipid A in sepsis and septic shock,” Biochemical and Biophysical Research Communications 182(1):269-275, Jan. 15, 1992. |
Ogawa et al., “Immunopharmacological activities of the nontoxic monophosphoryl lipd A of Porphyomonas gingivalis,” Vaccine 14(1):70-76, 1996. |
U.S. patent application Ser. No. 09/439,839, Johnson et al, filed Oct. 12, 1999. |
Johnson et al., “3-0-desacyl monophosphoryl lipid A derivatives: synthesis and immunostimulant activities,” J. Med. Chem. 42:4640-4649, 1999. |
Kirschning et al., “Human toll-like receptor 2 confers responsiveness to bacterial lipopolysaccharide,” J. Exp. Med. 188(11):2091-2097, Dec. 7, 1998. |
Poltorak et al., “Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene,” Science 282:2085-2088, Dec. 11, 1998. |
Qureshi et al., “Endotoxin-tolerant mice have mutations in toll-like receptor 4 (Tlr4),” J. Exp. Med. 189(4):615-625, Feb. 15, 1999. |
Ulrich and Meyers, in Vaccine Design: The Subunit and Adjuvant Approach: Powell and Newman Eds.; Plenum: New York, 495-524, 1995. |
Yang et al., “Toll-like receptor 2 mediates lipopolysaccharide-induced cellular signaling,” Nature 395:284-288, Sep. 17, 1998. |